# Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

> **NCT05624606** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 682 (actual)

## Conditions studied

- Influenza Immunization

## Interventions

- **BIOLOGICAL:** Quadrivalent Influenza mRNA Vaccine MRT5410
- **BIOLOGICAL:** Quadrivalent Recombinant Influenza vaccine RIV4
- **BIOLOGICAL:** Quadrivalent Inactivated Influenza Standard Dose QIV-SD
- **BIOLOGICAL:** Quadrivalent Inactivated Influenza High Dose QIV-HD

## Key facts

- **NCT ID:** NCT05624606
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-03-28
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624606, "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05624606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*